[{"id":"7235b2f2-0818-493f-a41a-c34684bbba42","acronym":"TRIUMPH","url":"https://clinicaltrials.gov/study/NCT03413995","created_at":"2021-01-18T16:50:34.963Z","updated_at":"2024-07-02T16:35:19.977Z","phase":"Phase 2","brief_title":"Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations","source_id_and_acronym":"NCT03413995 - TRIUMPH","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-09"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"88667f1b-98a0-4422-b87f-eee21f1cbfb9","acronym":"CHANGEABLE","url":"https://clinicaltrials.gov/study/NCT04508803","created_at":"2021-01-18T21:36:41.487Z","updated_at":"2024-07-02T16:36:08.019Z","phase":"Phase 2","brief_title":"Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer","source_id_and_acronym":"NCT04508803 - CHANGEABLE","lead_sponsor":"Fudan University","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 11/20/2022","primary_completion_date":" 11/20/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-06-30"}]